Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of rezafungin vs caspofungin/fluconazole for candidemia or invasive candidiasis
2018-002630-21Phase 3Completed
- Sponsor
- Cidara Therapeutics
- Start
- Nov 2018
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rezafungin in candidemia and invasive candidiasis (2 arms), sponsored by Cidara Therapeutics. Primary endpoint: Global cure at primary assessment time (EMA primary endpoint). Started Nov 2018; status: completed.
02
Drugs
rezafungin
03
Conditions
candidemiainvasive candidiasis
Beyond the preview
Go deeper on 2018-002630-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002630-21.